RT Journal Article
SR Electronic
T1 A double-blind controlled trial of long chain n-3 polyunsaturated fatty acids in the treatment of multiple sclerosis.
JF Journal of Neurology, Neurosurgery & Psychiatry
JO J Neurol Neurosurg Psychiatry
FD BMJ Publishing Group Ltd
SP 18
OP 22
DO 10.1136/jnnp.52.1.18
VO 52
IS 1
A1 D Bates
A1 N E Cartlidge
A1 J M French
A1 M J Jackson
A1 S Nightingale
A1 D A Shaw
A1 S Smith
A1 E Woo
A1 S A Hawkins
A1 J H Millar
YR 1989
UL http://jnnp.bmj.com/content/52/1/18.abstract
AB A trial of n-3 polyunsaturated fatty acids in the treatment of multiple sclerosis has been conducted over a 5 year period. Ambulant patients (312) with acute remitting disease were randomly allocated to treatment or placebo. Both groups were given dietary advice to increase the intake of n-6 polyunsaturated fatty acids and the treatment group in addition received capsules containing n-3 polyunsaturated fatty acids. Analysis of clinical outcome at the end of 2 years of treatment was made in terms of the duration, frequency and severity of relapses and the number of patients who had improved or remained unchanged. The results showed no significant difference at the usual 95% confidence limits but there was a trend in favour of the group treated with n-3 polyunsaturated fatty acids in all parameters examined.